Nonpeptidic lysosomal modulators derived from Z-Phe-Ala-diazomethylketone for treating protein accumulation diseases

ACS Medicinal Chemistry Letters

Volumn 3, Issue 11, 2012, Pages 920-924

  Viswanathan, Kishore ^a   Hoover, Dennis J ^b   Hwang, Jeannie ^a,c   Wisniewski, Meagan L ^c   Ikonne, Uzoma S ^c   Bahr, Ben A ^a,c   Wright, Dennis L ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Synaptic Dynamics Inc   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT PEMBROKE   (United States)

Author keywords

Alzheimer's disease; cathepsin B; lysosomal modulator; nonpeptidic inhibitors; PADK

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CATHEPSIN B; CATHEPSIN L; CYSTEINE PROTEINASE INHIBITOR; NOOTROPIC AGENT; SD 1002; SD 1003; TAU PROTEIN; UNCLASSIFIED DRUG; Z PHENYLALANYLALANINE DIAZOMETHYLKETONE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOSELECTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HIPPOCAMPUS; ISOMER; LYSOSOME; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; STEREOCHEMISTRY; UPREGULATION;

MUS MUSCULUS;

EID: 84868680638     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300197h     Document Type: Article

References (24)

1. Walsh, D. M.; Selkoe, D. J. Aβ oligomers-A decade of discovery J. Neurochem. 2007, 101, 1172-1184
2. Schneider, L. S.; Dagerman, K. S.; Higgins Julian, P. T.; McShane, R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease Arch. Neurol. 2011, 68, 991-998
3. Bendiske, J.; Caba, E.; Brown, Q. B.; Bahr, B. A. Intracellular deposition, microtubule destabilization, and transport failure: An "early" pathogenic cascade leading to synaptic decline J. Neuropathol. Exp. Neurol. 2002, 61, 640-650
4. Bahr, B. A.; Bendiske, J. The neuropathogenic contributions of lysosomal dysfunction J. Neurochem. 2002, 83, 481-489
5. Cataldo, A. M.; Barnett, J. L.; Berman, S. A.; Li, J.; Quarless, S.; Bursztejn, S.; Lippa, C.; Nixon, R. A. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: Evidence for early up-regulation of the endosomal-lysosomal system Neuron 1995, 14, 671-680
6. Callahan, L. M.; Vaules, W. A.; Coleman, P. D. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles J. Neuropathol. Exp. Neurol. 1999, 58, 275-287
7. Ginsberg, S. D.; Hemby, S. E.; Lee, V. M.; Eberwine, J. H.; Trojanowski, J. Q. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons Ann. Neurol. 2000, 48, 77-87
8. Nixon, R. A.; Mathews, P. M.; Cataldo, A. M. The neuronal endosomal-lysosomal system in Alzheimer's disease J. Alzheimer's Dis. 2001, 3, 97-107
9. Banay-Schwartz, M.; DeGuzman, T.; Kenessey, A.; Palkovits, M.; Lajtha, A. The distribution of cathepsin D activity in adult and aging human brain regions J. Neurochem. 1992, 58, 2207-2211
10. Bi, X.; Yong, A. P.; Zhou, J.; Gall, C. M.; Lynch, G. Regionally selective changes in brain lysosomes occur in the transition from young adulthood to middle age in rats Neuroscience (Oxford) 2000, 97, 395-404
11. Bendiske, J.; Bahr, B. A. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis-An approach for slowing Alzheimer disease? J. Neuropathol. Exp. Neurol. 2003, 62, 451-463
12. Butler, D.; Brown, Q. B.; Chin, D. J.; Batey, L.; Karim, S.; Mutneja, M. S.; Karanian, D. A.; Bahr, B. A. Cellular Responses to Protein Accumulation Involve Autophagy and Lysosomal Enzyme Activation Rejuvenation Res. 2005, 8, 227-237
13. Mueller-Steiner, S.; Zhou, Y.; Arai, H.; Roberson, E. D.; Sun, B.; Chen, J.; Wang, X.; Yu, G.; Esposito, L.; Mucke, L.; Gan, L. Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer's disease Neuron 2006, 51, 703-714
14. Bahr, B. A. Lysosomal modulatory drugs for a broad strategy against protein accumulation disorders Curr. Alzheimer Res. 2009, 6, 438-445
15. Ryzhikov, S.; Bahr, B. A. Gephyrin alterations due to protein accumulation stress are reduced by the lysosomal modulator Z-Phe-Ala- diazomethylketone J. Mol. Neurosci. 2008, 34, 131-139
16. Bahr, B. A.; Wisniewski, M. L.; Butler, D. Positive Lysosomal Modulation As a Unique Strategy to Treat Age-Related Protein Accumulation Diseases Rejuvenation Res. 2012, 15, 189-197
17. Butler, D.; Hwang, J.; Estick, C.; Nishiyama, A.; Kumar, S. S.; Baveghems, C.; Young-Oxendine, H. B.; Wisniewski, M. L.; Charalambides, A.; Bahr, B. A. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models PLoS One 2011, 6, e20501
18. Ghosh, A. K.; Thompson, W. J.; Holloway, M. K.; McKee, S. P.; Duong, T. T.; Lee, H. Y.; Munson, P. M.; Smith, A. M.; Wai, J. M. Potent HIV protease inhibitors: The development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands J. Med. Chem. 1993, 36, 2300-2310
19. Dubey, A. K.; Goswami, D.; Chattopadhyay, A. A simple and inexpensive procedure for low valent copper mediated benzylation of aldehydes in wet medium ARKIVOC (Gainesville, FL, U. S.) 2010, 137-145
20. Park, S.; Lee, S.; Kang, H. Efficient synthesis of 2(S)-[1(S)-azido-2- phenylethyl]oxirane Bull. Korean Chem. Soc. 2008, 29, 1073-1074
21. Turner, M. D.; Arvan, P. Protein traffic from the secretory pathway to the endosomal system in pancreatic β-cells J. Biol. Chem. 2000, 275, 14025-14030
22. Butler, D.; Hwang, J.; Estick, C.; Nishiyama, A.; Kumar, S. S.; Baveghems, C.; Young-Oxendine, H. B.; Wisniewski, M. L.; Charalambides, A.; Bahr, B. A. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models PLoS One 2011, 6, e20501
23. Parris, K. D.; Hoover, D. J.; Damon, D. B.; Davies, D. R. Synthesis and crystallographic analysis of two rhizopuspepsin inhibitor complexes Biochemistry 1992, 31, 8125-8141
24. Boger, J.; Payne, L. S.; Perlow, D. S.; Lohr, N. S.; Poe, M.; Blaine, E. H.; Ulm, E. H.; Schorn, T. W.; LaMont, B. I. Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analog inhibitors containing a novel analog of statine J. Med. Chem. 1985, 28, 1779-1790